MAIA Biotechnology (MAIA) said Tuesday that a combination of THIO and cemiplimab was well tolerated in patients with advanced non-small cell lung cancer in a phase 2 trial.
Results of the trial showed the safety, efficacy and ongoing benefit of the oncology therapy, the company said.
Six patients remain on treatment after more than 12 months of therapy, according to the company.
Price: 4.4000, Change: +0.65, Percent Change: +17.33
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments